China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Beijing’s action against clothing maker PVH and biotech company Illumina underlines risk created by trade tensions ...

On Monday, for the second time in as many business days, Illumina (NASDAQ: ILMN) stock took it on the chin because of an ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Shares of gene-sequencing leader Illumina have fallen 15% from Friday. Rivals 10X Genomics and Pacific BioSciences of ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to 2033" report has been added to ...